Trimel Pharmaceuticals Corporation
TSX : TRL

Trimel Pharmaceuticals Corporation

July 31, 2014 17:05 ET

Trimel Announces New TriVair™ Website

TORONTO, ONTARIO--(Marketwired - July 31, 2014) - Trimel Pharmaceuticals Corporation (TSX:TRL) announced today that the Company has launched a new website for its dry powder inhalation drug delivery platform TriVair™. Winner of the 2009 European Drug Delivery Product Differentiation Innovation of the Year Award, TriVair™ is Trimel's novel unit-dose dry powder inhaler / nasal dispersion device. Trimel is interested in establishing partnership arrangements with developers who are looking for a patented, novel dry powder nasal and pulmonary delivery system. For more information, please visit www.trivairdevice.com.

About Trimel

Trimel is a specialty pharmaceutical company involved in the sale, distribution, and development of products with a focus in men's health, women's health, and respiratory medicine. Natesto™, a product utilizing Trimel's licensed nasal gel technology, has been approved for sale in the United States by the FDA. For more information, please visit www.trimelpharmaceuticals.com.

Contact Information